Compare TNON & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNON | PMCB |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 4.0M |
| IPO Year | 2021 | 2001 |
| Metric | TNON | PMCB |
|---|---|---|
| Price | $0.91 | $4.28 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 95.4K | ★ 169.4K |
| Earning Date | 11-12-2026 | 12-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,944,000.00 | N/A |
| Revenue This Year | $44.38 | N/A |
| Revenue Next Year | $39.49 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 20.35 | N/A |
| 52 Week Low | $0.96 | $0.25 |
| 52 Week High | $40.95 | $8.17 |
| Indicator | TNON | PMCB |
|---|---|---|
| Relative Strength Index (RSI) | 22.15 | 67.19 |
| Support Level | N/A | $0.57 |
| Resistance Level | $4.18 | $8.17 |
| Average True Range (ATR) | 0.17 | 0.37 |
| MACD | -0.02 | 0.42 |
| Stochastic Oscillator | 4.65 | 49.86 |
Tenon Medical Inc is a medical device company that has minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.